Stockreport

Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready [Yahoo! Finance]

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF lesions demonstrated increasing uptake and strong retention with low healthy-organ (liver/kidney) background. Dosimetry estimates suggest projected therapeutic use of [Read more]